Sequencing methods and compositions for prenatal diagnoses

US12522869B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12522869-B2
Application numberUS-202318534929-A
CountryUS
Kind codeB2
Filing dateDec 11, 2023
Priority dateJan 19, 2010
Publication dateJan 13, 2026
Grant dateJan 13, 2026

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.

First claim

Opening claim text (preview).

The invention claimed is: 1 . A method for nucleic acid sequencing comprising: (a) providing a test sample comprising nucleic acid molecules, wherein said nucleic acid molecules are human cell-free DNA (cfDNA) molecules from a maternal plasma sample; (b) performing end-repair of the nucleic acid molecules to generate blunt-ended nucleic acids; (c) performing dA-tailing of the blunt-ended nucleic acids to generate dA-tailed nucleic acids; (d) ligating adaptors to the dA-tailed nucleic acids to generate a library of adaptor-ligated polynucleotides; and (e) subjecting the library to massively parallel sequencing; wherein steps (b), (c), and (d) are consecutive steps that exclude purifying the end-repaired products prior to the dA-tailing step and exclude purifying the dA-tailing products prior to the adaptor-ligating step, wherein said nucleic acid molecules of step (a), said blunt-ended nucleic acids of step (b), said dA-tailed nucleic acids of step (c), and said library of adaptor-ligated polynucleotides of step (d) are not subjected to fragmentation prior to consecutive steps (b), (c), and (d), and wherein said consecutive steps (b), (c), and (d) are performed in less than 1 hour and in the same reaction tube. 2 . The method of claim 1 , wherein said consecutive steps (b), (c), and (d) are performed in the absence of polyethylene glycol. 3 . The method of claim 1 , wherein said massively parallel sequencing comprises solid phase amplification to create a high density sequencing flow cell with millions of clusters. 4 . The method of claim 1 , wherein the library is amplified on beads and wherein each bead comprises a forward and reverse amplification primer. 5 . The method of claim 1 , wherein: said sequencing is massively parallel sequencing using sequencing-by-synthesis with reversible dye terminators; or said sequencing is massively parallel sequencing using sequencing-by-ligation. 6 . The method of claim 1 , wherein said sequencing comprises an amplification. 7 . The method of claim 1 , wherein said sequencing is single molecule sequencing. 8 . The method of claim 1 , further comprising amplifying the library using amplification primers prior to subjecting the library to massively parallel sequencing, said amplification primers comprising an adaptor-specific portion. 9 . The method of claim 1 , comprising obtaining sequencing reads of about 36 basepairs (bp) in length. 10 . The method of claim 1 , comprising amplifying a plurality of polymorphic target nucleic acids in a portion of the test sample. 11 . The method of claim 10 , wherein each of said plurality of polymorphic target nucleic acids comprises at least one single nucleotide polymorphism (SNP). 12 . The method of claim 11 , wherein said at least one SNP is a single SNP selected from rs560681, rs1109037, rs9866013, rs13182883, rs13218440, rs7041158, rs740598, rs10773760, rs4530059, rs7205345, rs8078417, rs576261, rs2567608, rs430046, rs99511 71, rs338882, rs10776839, rs9905977, rs1277284, rs258684, rs1347696, rs508485, rs9788670, rs8137254, rs3143, rs2182957, rs3739005, and rs530022. 13 . The method of claim 11 , wherein said at least one SNP is a tandem SNP selected from tandem SNP pairs rs7277033-rs2110153; rs2822654-rs1882882; rs368657-rs376635; rs2822731-rs2822732; rs1475881-rs7275487; rs1735976-rs2827016; rs447340-rs2824097; rs418989-rs13047336; rs987980-rs987981; rs4143392-rs4143391; rs1691324-rs13050434; rs11909758-rs9980111; rs2826842-rs232414; rs1980969-rs1980970; rs9978999-rs9979175; rs1034346-rs12481852; rs7509629-rs28283 58; rs481701 3-rs7277036; rs9981121-rs2829696; rs455921-rs2898102; rs2898102-rs458848; rs961301-rs2830208; rs2174536-rs458076; rs11088023-rs11088024; rs1011734-rs1011733; rs2831244-rs9789838; rs8132769-rs2831440; rs8134080-rs2831524; rs4817219-rs4817220; rs2250911-rs2250997; rs2831 899-rs2831900; rs2831902-rs2831903; rs11088086-rs2251447; rs2832040-rs11088088; rs2832141-rs2246777; rs2832959-rs9980934; rs2833734-rs2833735; rs933121-rs933122; rs2834140-rs12626953; rs2834485-rs3453; rs9974986-rs2834703; rs2776266-rs2835001; rs1984014-rs1984015; rs7281674-rs2835316; rs13047304-rs13047322; rs2835545-rs4816551; rs2835735-rs2835736; rs13047608-rs2835826; rs2836550-rs2212596; rs2836660-rs2836661; rs465612-rs8131220; rs9980072-rs8130031; rs418359-rs2836926; rs7278447-rs7278858; rs385787-rs367001; rs367001-rs386095; rs2837296-rs2837297; and rs2837381-rs4816672. 14 . The method of claim 10 , wherein each of said plurality of polymorphic target nucleic acids comprises at least one short tandem repeat (STR). 15 . The method of claim 14 , wherein said at least one STR is selected from CSF1PO, FGA, TH01, vWA, D3S1358, D5S818, D7S820, D8S1179, D13S317, D16S539, D18S51, D21S11, D2S1338, Penta D, Penta E, D22S1045, D20S1082, D20S482, D18S853, D17S1301, D17S974, D14S1434, D12ATA63, D11S4463, D10S1435, D10S1248, D9S2157, D9S1122, D8S1115, D6S1017, D6S474, D5S2500, D4S2408, D4S2364, D3S4529, D3S3053, D2S1776, D2S441, D1S1677, D1S1627, and D1GATA113.

Assignees

Inventors

Classifications

  • for data related to laboratory analysis, e.g. patient specimen analysis · CPC title

  • Disease subtyping, staging or classification · CPC title

  • Ploidy or copy number detection · CPC title

  • Sequence alignment; Homology search · CPC title

  • Methods for determination or identification of nucleic acids involving differential detection · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12522869B2 cover?
The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.
Who is the assignee on this patent?
Verinata Health Inc
What technology area does this patent fall under?
Primary CPC classification C12Q1/6806. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jan 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).